List of works - Nicholas S Mitsiades

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

scientific article published on September 2005

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

scientific article published in August 2002

Antimyeloma activity of heat shock protein-90 inhibition.

scientific article published on 18 October 2005

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

scientific article

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

scientific article published in June 2002

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

scientific article

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

scientific article published on July 2002

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

scientific article

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

scientific article published on 25 September 2003

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

scientific article published on 14 September 2009

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

scientific article published on September 2003

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

scientific article published on 24 November 2009

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

scientific article published on 26 September 2002

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

scientific article published on 16 January 2003

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

scientific article

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

scientific article published on July 2007

NF-kappa B as a therapeutic target in multiple myeloma

scientific article

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

scientific article

Novel biologically based therapies for Waldenstrom's macroglobulinemia

scientific article

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

scientific article published on 01 January 2003

Proteasome inhibition as a new therapeutic principle in hematological malignancies

scientific article published on October 2006

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

scientific article

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

scientific article published in November 2003

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

scientific article

Proteasome inhibitors as therapeutics

scientific article

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

scientific article published on 10 October 2006

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

scientific article published on 7 November 2002

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

scientific article published on 9 June 2006

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

scientific article published on 14 March 2010

List of works by Nicholas S Mitsiades

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Antimyeloma activity of heat shock protein-90 inhibition.

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

NF-kappa B as a therapeutic target in multiple myeloma

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

Novel biologically based therapies for Waldenstrom's macroglobulinemia

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

Proteasome inhibition as a new therapeutic principle in hematological malignancies

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

Proteasome inhibitors as therapeutics

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.